GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cadence Pharmaceuticals, Inc. (FRA:QEW) » Definitions » Equity-to-Asset

Cadence Pharmaceuticals, (FRA:QEW) Equity-to-Asset : 0.38 (As of Dec. 2013)


View and export this data going back to . Start your Free Trial

What is Cadence Pharmaceuticals, Equity-to-Asset?

Equity to Asset ratio is calculated as total stockholders equity divided by total asset. Cadence Pharmaceuticals,'s Total Stockholders Equity for the quarter that ended in Dec. 2013 was €25.46 Mil. Cadence Pharmaceuticals,'s Total Assets for the quarter that ended in Dec. 2013 was €66.29 Mil. Therefore, Cadence Pharmaceuticals,'s Equity to Asset Ratio for the quarter that ended in Dec. 2013 was 0.38.

The historical rank and industry rank for Cadence Pharmaceuticals,'s Equity-to-Asset or its related term are showing as below:

FRA:QEW's Equity-to-Asset is not ranked *
in the Biotechnology industry.
Industry Median: 0.66
* Ranked among companies with meaningful Equity-to-Asset only.

Cadence Pharmaceuticals, Equity-to-Asset Historical Data

The historical data trend for Cadence Pharmaceuticals,'s Equity-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cadence Pharmaceuticals, Equity-to-Asset Chart

Cadence Pharmaceuticals, Annual Data
Trend Dec04 Dec05 Dec06 Dec07 Dec08 Dec09 Dec10 Dec11 Dec12 Dec13
Equity-to-Asset
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.81 0.76 0.73 0.49 0.38

Cadence Pharmaceuticals, Quarterly Data
Mar09 Jun09 Sep09 Dec09 Mar10 Jun10 Sep10 Dec10 Mar11 Jun11 Sep11 Dec11 Mar12 Jun12 Sep12 Dec12 Mar13 Jun13 Sep13 Dec13
Equity-to-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.49 0.50 0.43 0.41 0.38

Competitive Comparison of Cadence Pharmaceuticals,'s Equity-to-Asset

For the Biotechnology subindustry, Cadence Pharmaceuticals,'s Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Cadence Pharmaceuticals,'s Equity-to-Asset Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Cadence Pharmaceuticals,'s Equity-to-Asset distribution charts can be found below:

* The bar in red indicates where Cadence Pharmaceuticals,'s Equity-to-Asset falls into.



Cadence Pharmaceuticals, Equity-to-Asset Calculation

Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.

Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.

Cadence Pharmaceuticals,'s Equity to Asset Ratio for the fiscal year that ended in Dec. 2013 is calculated as

Equity to Asset (A: Dec. 2013 )=Total Stockholders Equity/Total Assets
=25.461/66.286
=0.38

Cadence Pharmaceuticals,'s Equity to Asset Ratio for the quarter that ended in Dec. 2013 is calculated as

Equity to Asset (Q: Dec. 2013 )=Total Stockholders Equity/Total Assets
=25.461/66.286
=0.38

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Cadence Pharmaceuticals,  (FRA:QEW) Equity-to-Asset Explanation

Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.

For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.


Cadence Pharmaceuticals, Equity-to-Asset Related Terms

Thank you for viewing the detailed overview of Cadence Pharmaceuticals,'s Equity-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.


Cadence Pharmaceuticals, Business Description

Traded in Other Exchanges
N/A
Address
Cadence Pharmaceuticals, Inc. is a biopharmaceutical company focused on in-licensing, developing and commercializing product candidates mainly for use in the hospital setting. The Company's main activities are conducting research and development activities as well as conducting clinical trials. The company has in-licensed rights to products: Acetavance, an intravenous formulation of acetaminophen, and Omigard, an omiganan pentahydrochloride 1% aqueous gel. It in-licensed the exclusive United States, or U.S., and Canadian rights to Acetavance from Bristol-Myers Squibb Company, or BMS, which markets this product candidate in Europe and other markets for the treatment of acute pain and fever under the brand name Perfalgan. The Company is developing Acetavance, a proprietary intravenous formulation of acetaminophen, for the U.S. market for the treatment of acute pain and fever in adults and children. In its oral form, acetaminophen is the most widely used drug for the treatment of pain and fever in the U.S. The Company's licensor, BMS, currently markets this proprietary intravenous formulation of acetaminophen for the treatment of acute pain and fever in Europe and several other markets outside the U.S, where it is known as paracetamol and is marketed under the brand name Perfalgan.

Cadence Pharmaceuticals, Headlines

No Headlines